• New publication in Nature shows therapeutic silencing of microRNA-33a/b for atherosclerosis:
    Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
    K.J. Rayner et al.
    Nature 478, 404–407 (20 October 2011)

    Pre-clinical Data on miR-133
  • Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
  • Company to host webinar on October 26, 2011 to discuss findings

regulus therapeutics logoLA JOLLA, Calif., Oct. 20, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and collaborators at NYU Langone Medical Center and Wake Forest Baptist Medical Center today announced the publication of new pre-clinical research findings in the journal Nature (Rayner et al., Nature, October 20, 2011). The new data show the first demonstration of marked increases in high density lipoprotein cholesterol (HDL-C), the ‘good’ cholesterol, and suppression of plasma triglyceride levels in non-human primates through inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with proprietary chemically modified anti-miR oligonucleotides. A webinar to discuss the new data will be hosted by Regulus and features Kathryn Moore, Ph.D., associate professor in the Department of Medicine at NYU Langone Medical Center and Regulus scientists (11:00am EDT, October 26, 2011).

“In addition to atherosclerotic plaque regression and enhanced reverse cholesterol transport that we previously observed in rodents with our collaborators at NYU Langone Medical Center, anti-miR-33 treatment is now shown to [click to continue…]

Incoming search terms for this article:


microRNA 21 ArticlemicroRNA-21 is a very popular study target these days, which is not surprising given its overexpression in many human tumors, and was profiled on the miRNA blog back in February as the “microRNA of the week”.

Researchers at Yale have now demonstrated what they call ‘oncomiR addiction’ (the dependence of some cancer types on certain microRNAs for maintenance of the malignant phenotype) for miR-21 by pre-B-cell lymphoma. They show for the first time in vitro that overexpression of miR-21 leads to a pre-B malignant lymphoid-like phenotype and that when miR-21 is inactivated, the tumors regress completely in a few days. Their research not only demonstrates that mir-21 is a genuine oncogene but that tumors can also become addicted to oncomiRs. This and other work supports miR-21 as a drug target for treatment of human cancers.

Medina PP, Nolde M, Slack FJ (2010) OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature [Epub ahead of print]. [abstract]

{ 1 comment }

MicroRNAs…not fossils

by Chris on February 2, 2010

in Publications

The last ancestor we shared with worms lived 600 million years ago and may already have had a sophisticated brain that released hormones into the blood and was connected to various sensory organs. The evidence comes not from a newly found fossil, but from the study of microRNAs in a group of animals alive today representing an outgroup to the bilaterians, Platynereis dumerilii, a protostome retaining ancestral bilaterian features, Capitella, another marine annelid, the sea urchin Strongylocentrotus, a deuterostome, and the sea anemone Nematostella. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, have discovered that these molecules are found in the exact same tissues in animals as diverse as sea anemones, worms, and humans, hinting at an early origin of these tissues in animal evolution.  (read more…)

Christodoulou F, Raible F, Tomer R, Simakov O, Trachana K, Klaus S, Snyman H, Hannon GJ, Bork P, Arendt D. (2010) Ancient animal microRNAs and the evolution of tissue identity. Nature [Epub ahead of print] [abstract]


microRNAs Supplement – Nature

by Chris on December 18, 2009

in Publications

coverMicroRNAs (miRNAs) are small, non–coding RNAs found in plants and animals. They regulate gene expression by binding to complementary sequences within target mRNAs. The mammalian genome encodes hundreds of miRNAs that collectively affect the expression of about one–third of all genes. This collection showcases the latest papers from Nature that explore the biogenesis, biological effects in both normal and diseased cells, and therapeutic potential of miRNAs. (read more)